143 related articles for article (PubMed ID: 37860779)
21. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
[TBL] [Abstract][Full Text] [Related]
22. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Blumenthal J; Jain S; He F; Amico KR; Kofron R; Ellorin E; Stockman JK; Psaros C; Ntim GM; Chow K; Anderson PL; Haubrich R; Corado K; Moore DJ; Morris S; Landovitz RJ
Clin Infect Dis; 2021 Oct; 73(7):1149-1156. PubMed ID: 33864370
[TBL] [Abstract][Full Text] [Related]
23. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
Wheeler DP; Fields SD; Beauchamp G; Chen YQ; Emel LM; Hightow-Weidman L; Hucks-Ortiz C; Kuo I; Lucas J; Magnus M; Mayer KH; Nelson LE; Hendrix CW; Piwowar-Manning E; Shoptaw S; Watkins P; Watson CC; Wilton L
J Int AIDS Soc; 2019 Feb; 22(2):e25223. PubMed ID: 30768776
[TBL] [Abstract][Full Text] [Related]
24. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa.
Khadka N; Gorbach PM; Nyemba DC; Mvududu R; Mashele N; Javanbakht M; Nianogo RA; Aldrovandi GM; Bekker LG; Coates TJ; Myer L; Joseph Davey DL
Front Reprod Health; 2023; 5():1224474. PubMed ID: 37795521
[TBL] [Abstract][Full Text] [Related]
26. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
27. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
31. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
Sivay MV; Li M; Piwowar-Manning E; Zhang Y; Hudelson SE; Marzinke MA; Amico RK; Redd A; Hendrix CW; Anderson PL; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant R; Eshleman SH;
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):271-279. PubMed ID: 28328548
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Celum C; Baeten JM
Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
[TBL] [Abstract][Full Text] [Related]
33. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
Mitchell KM; Boily MC; Hanscom B; Moore M; Todd J; Paz-Bailey G; Wejnert C; Liu A; Donnell DJ; Grinsztejn B; Landovitz RJ; Dimitrov DT
Lancet Reg Health Am; 2023 Feb; 18():100416. PubMed ID: 36844011
[TBL] [Abstract][Full Text] [Related]
34. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
[TBL] [Abstract][Full Text] [Related]
35. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.
Koss CA; Bacchetti P; Hillier SL; Livant E; Horng H; Mgodi N; Mirembe BG; Gomez Feliciano K; Horn S; Liu AY; Glidden DV; Grant RM; Benet LZ; Louie A; van der Straten A; Chirenje ZM; Marrazzo JM; Gandhi M
AIDS Res Hum Retroviruses; 2017 Aug; 33(8):778-783. PubMed ID: 28253024
[TBL] [Abstract][Full Text] [Related]
36. A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIV-negative women planning for or with pregnancy in rural Southwestern Uganda.
Atukunda EC; Owembabazi M; Pratt MC; Psaros C; Muyindike W; Chitneni P; Bwana MB; Bangsberg D; Haberer JE; Marrazzo J; Matthews LT
J Int AIDS Soc; 2022 Mar; 25(3):e25894. PubMed ID: 35324081
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
38. Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Donnell D; Gao F; Hughes JP; Hanscom B; Corey L; Cohen MS; Edupuganti S; Mgodi N; Rees H; Baeten JM; Gray G; Bekker LG; Hosseinipour M; Delany-Moretlwe S
J Int AIDS Soc; 2023 Jun; 26(6):e26118. PubMed ID: 37363917
[TBL] [Abstract][Full Text] [Related]
39. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
[TBL] [Abstract][Full Text] [Related]
40. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
